背景眼压(IOP)是原发性开角型青光眼(POAG)的高度遗传性危险因素,至少有27个相关基因;然而,我们仍然不知道大麻的主要成分使用哪些受体或基因来降低IOP.方法在目前的研究中,我们使用英国生物库(UKBB)的数据评估了37,046名受试者中生长停滞特异性7(GAS7)与IOP和大麻的关系.GAS7位于染色体17p31.1,与染色体17p31.3的大麻受体非常接近。为了比较,我们选择了第二个眼压/青光眼基因,9p21.3染色体上的CDKN2B-AS1,与大麻无已知关系。此外,我们检测了CB1,GPR18和大麻对小鼠眼内压的影响;这两个基因与大麻眼内压降低相关.结果在37,046名受试者中,大麻总使用量与IOP和GAS7SNPrs9913911基因型之间存在显着差异[p<0.001,单变量方差分析(ANOVA)]。GAS7rs9913911次要等位基因G的携带者随着大麻使用的增加而具有较低的IOP。37,046名受试者中CDKN2B-AS1SNPrs944801基因型的总大麻使用与IOP相比具有IOP变异性,大麻使用不显著(p=0.138)。我们分析了CB1SNPrs806365和GPR18SNPrs3742130与大麻使用和IOP的关系,这是微不足道的。CB1和GPR18可能不参与大麻相关的人眼压降低,不像在老鼠身上报道的那样。结论以大麻为基础的治疗,它显然作用于GAS7基因,可用于降低IOP。然而,他们的缺点大于他们的优点,当大麻对IOP的影响的最初报告在20世纪70年代发表时,情况并非如此。因此,以大麻为基础的青光眼治疗现在的价值值得怀疑。
Background Intraocular pressure (IOP) is a highly heritable risk factor for primary open-angle glaucoma (POAG), with at least 27 related genes; however, we are still not aware as to which receptors or genes that the main components of cannabis use to lower IOP. Methods In the current study, we used data from the UK Biobank (UKBB) to assess the relationship of growth arrest-specific 7 (
GAS7) with IOP and cannabis in 37,046 subjects.
GAS7, at chromosome 17p31.1, is quite close to a cannabis receptor at chromosome 17p31.3. For comparison, we chose a second IOP/glaucoma gene, CDKN2B-AS1 on chromosome 9p21.3, with no known relationship to cannabis. In addition, we examined the effect of CB1, GPR18, and cannabis on IOP; these two genes are associated with cannabis IOP reduction in mice. Results Total cannabis use versus IOP and genotypes of
GAS7 SNP rs9913911 in the 37,046 subjects showed significant variation [p<0.001, univariate analysis of variance (ANOVA)]. Carriers of the
GAS7 rs9913911 minor allele G had lower IOP with increased cannabis use. Total cannabis use versus IOP of genotypes of CDKN2B-AS1 SNP rs944801 in 37,046 subjects had IOP variability with cannabis use that was insignificant (p=0.138). We analyzed the relationship of CB1 SNP rs806365 and GPR18 SNP rs3742130 with cannabis use and IOP, which was insignificant. CB1 and GPR18 are probably not involved in cannabis-associated human IOP reduction, unlike what has been reported in mice. Conclusion Cannabis-based treatments, which apparently act on the
GAS7 gene, can be utilized to reduce IOP. However, their disadvantages outweigh their advantages, which was not the case when the initial reports of marijuana\'s effects on IOP were published in the 1970s. Hence, cannabis-based glaucoma treatments are now of questionable value.